Giles Thomas D, Sander Gary E
Section of Cardiology, Louisiana State University Health Sciences Center, 1542 Tulane Avenue, New Orleans, LA 70112, USA.
Cardiol Clin. 2004 Nov;22(4):553-68. doi: 10.1016/j.ccl.2004.07.002.
Diabetic cardiomyopathy encompasses the spectrum from subclinical disease to the full-blown syndrome of congestive heart failure. The prevalence of type 2 diabetes mellitus is increasing at an alarming rate in the western world. and with it, the frequency of diabetes-related heart failure. There is at least early suggestion that target-driven, long-term, intensified intervention that is aimed at multiple risk factors in patients who have type 2 diabetes and microalbuminuria may reduce the risk of macrovascular (cardiovascular) and micro-vascular complications by approximately 50%. Thus, it is imperative that patients, particularly those who are at risk for the cardiovascular dysmetabolic syndrome, be screened aggressively for the presence of glucose intolerance and diabetes. When detected, all metabolic and cardio-vascular parameters should be evaluated and treated aggressively to reach currently recommended clinical targets. Such action will result in great benefit for patients by reducing morbidity and mortality and improving quality of life and will reduce the financial burden that is associated with this epidemic disease.
糖尿病性心肌病涵盖了从亚临床疾病到充血性心力衰竭全面发作综合征的整个范围。在西方世界，2型糖尿病的患病率正以惊人的速度上升，与之相伴的是糖尿病相关心力衰竭的发生率也在上升。至少有早期迹象表明，针对2型糖尿病和微量白蛋白尿患者的多种危险因素进行目标驱动的长期强化干预，可能会将大血管（心血管）和微血管并发症的风险降低约50%。因此，必须积极筛查患者，尤其是那些有心血管代谢综合征风险的患者，以确定是否存在葡萄糖不耐受和糖尿病。一旦检测到，应积极评估和治疗所有代谢和心血管参数，以达到当前推荐的临床目标。这样的行动将通过降低发病率和死亡率、改善生活质量，给患者带来巨大益处，并将减轻与这种流行病相关的经济负担。
